MX2011011514A - Formulaciones de canabidiol y metodos para utilizarlas. - Google Patents

Formulaciones de canabidiol y metodos para utilizarlas.

Info

Publication number
MX2011011514A
MX2011011514A MX2011011514A MX2011011514A MX2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A
Authority
MX
Mexico
Prior art keywords
canabidiol
methods
formulations
cannabinoid
pharmaceutical compositions
Prior art date
Application number
MX2011011514A
Other languages
English (en)
Spanish (es)
Inventor
Audra Lynn Stinchcomb
Stan Lee Banks
Original Assignee
Alltranz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltranz Inc filed Critical Alltranz Inc
Publication of MX2011011514A publication Critical patent/MX2011011514A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
MX2011011514A 2009-04-28 2010-04-28 Formulaciones de canabidiol y metodos para utilizarlas. MX2011011514A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17346909P 2009-04-28 2009-04-28
PCT/US2010/032822 WO2010127033A1 (en) 2009-04-28 2010-04-28 Formulations of cannabidiol and methods of using the same

Publications (1)

Publication Number Publication Date
MX2011011514A true MX2011011514A (es) 2011-11-18

Family

ID=42246015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011514A MX2011011514A (es) 2009-04-28 2010-04-28 Formulaciones de canabidiol y metodos para utilizarlas.

Country Status (6)

Country Link
US (1) US20100273895A1 (enExample)
EP (1) EP2424525A1 (enExample)
JP (1) JP5801794B2 (enExample)
CA (1) CA2760460C (enExample)
MX (1) MX2011011514A (enExample)
WO (1) WO2010127033A1 (enExample)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
US9492097B2 (en) 2007-11-26 2016-11-15 C. R. Bard, Inc. Needle length determination and calibration for insertion guidance system
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
ES2651898T3 (es) 2007-11-26 2018-01-30 C.R. Bard Inc. Sistema integrado para la colocación intravascular de un catéter
US9456766B2 (en) 2007-11-26 2016-10-04 C. R. Bard, Inc. Apparatus for use with needle insertion guidance system
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
US9901714B2 (en) 2008-08-22 2018-02-27 C. R. Bard, Inc. Catheter assembly including ECG sensor and magnetic assemblies
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
EP3542713A1 (en) 2009-06-12 2019-09-25 Bard Access Systems, Inc. Adapter for a catheter tip positioning device
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
EP2464407A4 (en) 2009-08-10 2014-04-02 Bard Access Systems Inc DEVICES AND METHODS FOR ENDOVASCULAR ELECTROGRAPHY
EP2482719A4 (en) 2009-09-29 2016-03-09 Bard Inc C R STYLETS FOR USE WITH APPARATUS FOR INTRAVASCULAR PLACEMENT OF A CATHETER
US11103213B2 (en) 2009-10-08 2021-08-31 C. R. Bard, Inc. Spacers for use with an ultrasound probe
US10639008B2 (en) 2009-10-08 2020-05-05 C. R. Bard, Inc. Support and cover structures for an ultrasound probe head
EP2531098B1 (en) 2010-02-02 2020-07-15 C.R. Bard, Inc. Apparatus and method for catheter navigation and tip location
EP3662827B1 (en) 2010-05-28 2021-03-03 C.R. Bard, Inc. Apparatus for use with needle insertion guidance system
KR101856267B1 (ko) 2010-08-20 2018-05-09 씨. 알. 바드, 인크. Ecg-기반 카테터 팁 배치의 재확인
HUE026929T2 (en) * 2010-10-19 2016-08-29 Parenteral A S A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
CN103189009B (zh) 2010-10-29 2016-09-07 C·R·巴德股份有限公司 医疗设备的生物阻抗辅助放置
US12318420B2 (en) 2010-12-01 2025-06-03 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US11344505B1 (en) * 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
USD724745S1 (en) 2011-08-09 2015-03-17 C. R. Bard, Inc. Cap for an ultrasound probe
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
JP5820207B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP5820206B2 (ja) * 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
US9211107B2 (en) 2011-11-07 2015-12-15 C. R. Bard, Inc. Ruggedized ultrasound hydrogel insert
EP2861153A4 (en) 2012-06-15 2016-10-19 Bard Inc C R APPARATUS AND METHODS FOR DETECTION OF A REMOVABLE CAP ON AN ULTRASONIC PROBE
EP2968259B1 (en) * 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
ES2538335T3 (es) * 2013-05-14 2015-06-19 Najöpharm Gmbh I.G. Combinación de ácido poliacrílico y 2-amino-2-metilpropanol para uso en el tratamiento de infecciones por herpes
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
WO2016187722A1 (en) * 2015-05-27 2016-12-01 Mary Lynch Use of cannabinoids in the treatment of ocular inflammation and/or pain
CN105979868B (zh) 2014-02-06 2020-03-10 C·R·巴德股份有限公司 用于血管内装置的导向和放置的系统和方法
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
US20160015818A1 (en) * 2014-07-18 2016-01-21 Medipath, Inc. Compositions and methods for physiological delivery using cannabidiol
WO2016014419A1 (en) * 2014-07-21 2016-01-28 Glia, Llc Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10398776B1 (en) 2014-11-03 2019-09-03 Essential Green Goodness LLC Phonophoretic cannabidiol composition and transdermal delivery system
CA2971144A1 (en) * 2014-12-17 2016-06-23 One World Cannabis Ltd Novel condom comprising cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms
US20180020699A1 (en) * 2014-12-19 2018-01-25 Thc Pharm Gmbh The Health Concept Cbd-containing beverage
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
AU2016226267A1 (en) * 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
WO2016191651A1 (en) 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
GB2544468A (en) * 2015-11-12 2017-05-24 Jaytee Biosciences Ltd Liquid formulation
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
CA3021660A1 (en) 2016-04-22 2017-10-26 Receptor Life Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
US20190184364A1 (en) * 2016-05-03 2019-06-20 International Flavors & Fragrances Inc. Fragrance compositions containing microcapsules
KR102295739B1 (ko) 2016-05-03 2021-08-30 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US20190030170A1 (en) * 2016-05-10 2019-01-31 Vireo Health LLC Cannabinoid formulations with improved solubility
WO2018071452A1 (en) 2016-10-11 2018-04-19 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018083697A1 (en) * 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CA3052146A1 (en) 2017-02-01 2018-08-09 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
BR112019017049A2 (pt) * 2017-02-15 2020-04-14 Botanix Pharmaceuticals Ltd formulações de canabinoides para o tratamento de acne
US10231948B2 (en) 2017-02-27 2019-03-19 Jason Ty Nguyen Metered dose inhaler compositions, systems, and methods
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
WO2019018705A1 (en) * 2017-07-21 2019-01-24 Masaya World, Llc CAPRYLIC ACID ENRICHED IN CANNABIDIOL
WO2019034936A2 (en) * 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd TERPENE ENRICHED CANNABINOID COMPOSITION AND PROCESSING METHOD
WO2019034985A1 (en) * 2017-08-14 2019-02-21 Zynerba Pharmaceuticals, Inc. METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
CA3075719A1 (en) 2017-09-19 2019-03-28 Zynerba Pharmaceuticals, Inc. Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
WO2019056123A1 (en) 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
ES2992838T3 (en) * 2017-09-28 2024-12-18 Harmony Biosciences Man Inc Treatment of irritability in autism spectrum disorder with cannabidiol
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
CN111801093A (zh) * 2017-10-17 2020-10-20 雷米生物科学公司 用于包括cbd增强的组合物、制剂和嵌合体的部分的改善的递送系统
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
KR102063524B1 (ko) * 2017-11-10 2020-01-08 안용훈 칸나비디올을 포함하는 화장료 조성물
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201720992D0 (en) * 2017-12-15 2018-01-31 Hooper Mark A medical use
EP3743054A4 (en) * 2018-01-24 2021-11-10 Botanix Pharmaceuticals Ltd CANNABINOID DOSING SCHEME FOR DERMATITIS AND INFLAMMATORY SKIN DISEASES
AU2019210704A1 (en) * 2018-01-24 2020-08-06 Botanix Pharmaceuticals Ltd Cannabinoid dosing regime for psoriasis
JP2021512067A (ja) * 2018-01-24 2021-05-13 ボタニクス ファーマシューティカルズ リミテッド ざ瘡のためのカンナビノイド投薬レジメン
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CA3098582A1 (en) * 2018-04-27 2019-10-31 Remy Biosciences, Inc. New medical devices, delivery vehicles and manufacturing thereof
US11096904B2 (en) 2018-05-11 2021-08-24 Linda J. Kaplan Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia
US20200009078A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Oral compositions
US10588979B1 (en) * 2018-09-17 2020-03-17 Cody D. Freeze Cannabinoid and terpene-infused topical cream
CN112867443B (zh) 2018-10-16 2024-04-26 巴德阿克塞斯系统股份有限公司 用于建立电连接的安全装备连接系统及其方法
CA3120001A1 (en) 2018-11-19 2020-05-28 Receptor Holdings, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
WO2020123809A1 (en) 2018-12-14 2020-06-18 Natural Extraction Systems, LLC Compositions and methods related to anionic cannabinoid molecules
KR20210104084A (ko) 2018-12-14 2021-08-24 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
WO2020139851A1 (en) * 2018-12-26 2020-07-02 Clear Lake Research, Llc Delivery of health benefits through component formulation
US20220184003A1 (en) * 2019-02-06 2022-06-16 Emerald Health Pharmaceuticals Inc Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2)
IT201900003325A1 (it) * 2019-03-07 2020-09-07 C I A M S R L Composizione per la prevenzione e trattamento della dermatite atopica
US20230414492A1 (en) * 2019-04-02 2023-12-28 Nose To Brain Therapeutics Llc Intranasal delivery of cannabidiol to treat central nervous system disorders
WO2020206205A1 (en) * 2019-04-03 2020-10-08 Willow Bark Brands, Inc Dosage forms and methods of preparation and use thereof
US11806645B1 (en) 2019-05-07 2023-11-07 Cannaceutical Extractions LLC Methods of producing CBD/THC oils
US12029707B2 (en) 2019-05-28 2024-07-09 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
US11931333B1 (en) * 2019-05-28 2024-03-19 Peter Van Horn Topical treatment of herpes infections
WO2020243352A1 (en) * 2019-05-28 2020-12-03 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
EP3986395A4 (en) * 2019-06-18 2023-08-09 Botanix Pharmaceuticals Ltd ANTIBACTERIAL DOSAGE REGIMEN USING CANNABINOIDS
CN114423412A (zh) * 2019-08-05 2022-04-29 Cs医学股份有限公司 包含大麻二酚的外用制剂、制备组合物的方法及其用途
WO2021042001A1 (en) * 2019-08-30 2021-03-04 Natural Extraction Systems, LLC Compositions and methods related to dissolved oxides
US20210169820A1 (en) 2019-09-12 2021-06-10 Nulixir Inc. Controlled release concentrate and suspensions including the same
EP4031119B1 (en) 2019-09-17 2025-12-17 Harmony Biosciences Management, Inc. Transdermal treatment of behavioral impairment in developmental and epileptic encephalopathy with cbd
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
MX2022004257A (es) * 2019-10-11 2022-05-26 Pike Therapeutics Inc Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
AU2020368344A1 (en) 2019-10-13 2022-04-14 Fibrobiologics, Inc. Cannabidiol adjuvant therapy for treatment of disc degenerative disease
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
MX2022004258A (es) * 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
WO2021087291A1 (en) * 2019-10-31 2021-05-06 Natural Extraction Systems, LLC Compositions and methods related to organic oxides
US12350252B2 (en) * 2019-12-31 2025-07-08 Soluscience, Llc Water-soluble cannabinoid formulations and methods of their making
WO2021150595A1 (en) * 2020-01-20 2021-07-29 Nutramax Laboratories, Inc. Novel formulations comprising cannabis
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
AU2021259495A1 (en) * 2020-04-20 2022-10-27 Pike Therapeutics, Inc. Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
US11998514B2 (en) 2020-05-21 2024-06-04 Elementis Specialties, Inc. Cannabidiol and active delivery systems
EP4157236A1 (en) 2020-05-26 2023-04-05 Zynerba Pharmaceuticals, Inc. Treatment of autism spectrum disorder with cannabidiol
BR112022026044A2 (pt) 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20230131989A1 (en) * 2020-07-29 2023-04-27 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
WO2022026960A1 (en) 2020-07-31 2022-02-03 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
GB202012836D0 (en) 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition
CN115884750A (zh) * 2020-08-21 2023-03-31 联合利华知识产权控股有限公司 防腐剂体系和包含其的组合物
CA3201666A1 (en) 2020-11-16 2022-05-19 SYNERGY LIFE SCIENCE, Inc. Cannabinoid emulsifier
AU2021393122A1 (en) * 2020-12-03 2023-06-29 Pike Therapeutics Inc. Transdermal pharmaceutical formulations comprising cbd or thc for the treatment of cancer
IL303388A (en) 2020-12-03 2023-08-01 Zynerba Pharmaceuticals Inc Treatment of refractory convulsions
KR20230137404A (ko) 2021-01-28 2023-10-04 지네르바 파마슈티컬스, 인코포레이티드 Cbd를 사용한 수면 무호흡증의 치료
CN116940343A (zh) 2021-02-05 2023-10-24 Cs 医学股份有限公司 关节炎和银屑病的补充剂
EP4319730A4 (en) * 2021-04-08 2025-03-12 Pike Therapeutics, Inc. PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING EPILEPTIC DISORDERS
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4326252A4 (en) * 2021-04-22 2025-03-12 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of chronic pain
DK181458B1 (en) * 2021-05-06 2024-01-31 Cs Medica As Wound treatment composition, use thereof and method for providing said composition
DK181405B1 (en) 2021-05-25 2023-10-17 Cs Medica As Gel for Intranasal Application, its Provision and Use
WO2022271848A1 (en) 2021-06-22 2022-12-29 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
US12064461B2 (en) * 2021-07-16 2024-08-20 Avicanna Inc. Deep penetrating topical cannabinoid compositions and methods for treating musculoskeletal inflammation and pain
CA3234880A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
JP2024536581A (ja) 2021-10-22 2024-10-04 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 中等度から重度の不安及び／又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療
EP4422769A2 (en) 2021-10-26 2024-09-04 Ecofibre USA Inc. Systems and methods for producing hemp extracts and compositions
JP2024540177A (ja) 2021-10-26 2024-10-31 エコファイバー ユーエスエイ インコーポレイテッド ヘンプ抽出物を使用する子宮内膜がんを処置する方法
WO2023076937A1 (en) 2021-10-26 2023-05-04 Ecofibre Limited Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
US20230404910A1 (en) * 2022-06-16 2023-12-21 Stephanie Gore Implantable cannabis transdermal
EP4558199A1 (en) 2022-07-18 2025-05-28 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method
EP4608426A1 (en) 2022-10-26 2025-09-03 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
US12097211B2 (en) 2022-10-26 2024-09-24 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract
WO2024158861A1 (en) * 2023-01-24 2024-08-02 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
WO2024234014A1 (en) * 2023-05-11 2024-11-14 Spiritus Bioscience, Inc. Sublingual spray formulations of psychedelics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use

Also Published As

Publication number Publication date
CA2760460C (en) 2019-04-02
WO2010127033A1 (en) 2010-11-04
JP2012525416A (ja) 2012-10-22
CA2760460A1 (en) 2010-11-04
JP5801794B2 (ja) 2015-10-28
US20100273895A1 (en) 2010-10-28
EP2424525A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
PE20140936A1 (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
ECSP11010818A (es) Métodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
CO7131352A2 (es) Composiciones farmacéuticas tópicas
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2014012742A (es) Composicion para el tratamiento de transtornos metabólicos.
PE20180026A1 (es) Composicion topica curativa
DOP2016000007A (es) Pirazolpiridinas sustituidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal